184 related articles for article (PubMed ID: 7864679)
1. [Serum and tissue quantification of tissue polypeptide antigen (TPA) in transitional cell carcinoma of the bladder].
Moreno Sierra J; Maestro de las Casas ML; Ortega Heredia MD; Blanco Jimenez E; Hermida Gutiérrez J; Resel Estévez L
Arch Esp Urol; 1994 Dec; 47(10):979-84. PubMed ID: 7864679
[TBL] [Abstract][Full Text] [Related]
2. [Advances regarding tumor markers in bladder cancer].
Moreno Sierra J; Chicharro Almarza GJ; Torronteras Santiago JM; Ortega Heredia MD; Maestro de las Casas ML; Silmi Moyano A; Resel Estévez L
Actas Urol Esp; 1997 Mar; 21(3):195-205. PubMed ID: 9324884
[TBL] [Abstract][Full Text] [Related]
3. [The clinical significance of serum tissue polypeptide antigen as a tumor marker for urogenital carcinomas--a comparison with other tumor markers in patients with renal cell carcinoma and prostatic carcinoma].
Yamazaki K; Kumamoto Y; Tsukamoto T; Umehara T; Ohmura K
Hinyokika Kiyo; 1987 Oct; 33(10):1581-9. PubMed ID: 2451408
[TBL] [Abstract][Full Text] [Related]
4. Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma.
Yao WJ; Chang CJ; Chan SH; Chow NH; Cheng HL; Tzai TS; Lin SN
Anticancer Res; 1995; 15(6B):2819-23. PubMed ID: 8669871
[TBL] [Abstract][Full Text] [Related]
5. [The usefulness of the carbohydrate antigen CA-50 in the prognosis of transitional-cell bladder carcinomas].
Moreno Sierra J; Blanco Jímenez E; Silmi Moyano A; Ortega Heredia MD; Páramo González P; Maestro de las Casas ML; Fernández Lucas C; Ramírez Fernández JC; Luengo Alpuente S; Gómez Vegas A
Arch Esp Urol; 1993 Nov; 46(9):775-8. PubMed ID: 8304791
[TBL] [Abstract][Full Text] [Related]
6. Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer.
van Poppel H; Billen J; Goethuys H; Elgamal AA; Gerits M; Mortelmans L; Blanckaert N; Baert L
Anticancer Res; 1996; 16(4B):2205-7. PubMed ID: 8694544
[TBL] [Abstract][Full Text] [Related]
7. Tissue polypeptide antigen in normal and neoplastic urinary bladder. Preliminary reports.
Senatore S; Attolini A; Luccarelli S; Candita F; Trabucco M
Oncology; 1987; 44(2):118-23. PubMed ID: 2437508
[TBL] [Abstract][Full Text] [Related]
8. [Determination of serum SCC antigen in transitional cell carcinoma of the bladder].
Moreno Sierra J; Maestro de las Casas M; Ortega Heredia MD; Rodríguez Molina J; López Asenjo J; Blanco Jiménez E; Hermida Gutiérrez J; Esteban Fuertes M; Resel Estevez L
Actas Urol Esp; 1994 Jan; 18(1):26-8. PubMed ID: 8191942
[TBL] [Abstract][Full Text] [Related]
9. Tissue polypeptide specific antigen (TPS) as a tumor marker in nasopharyngeal carcinoma.
Sun SS; Hsieh JF; Tsai SC; Ho YJ; Kao CH
Anticancer Res; 2000; 20(6C):4661-3. PubMed ID: 11205197
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
[TBL] [Abstract][Full Text] [Related]
11. Comparison between tissue antigen analysis and plasma determinations for TPA and CEA in transitional cell carcinomas and in tumorfree urothelium of the urinary bladder.
Vogel J; Oehr P; Maisey R; Adolphs HD
Cancer Detect Prev; 1988; 11(3-6):389-96. PubMed ID: 2455597
[TBL] [Abstract][Full Text] [Related]
12. [Tumor bladder antigen (TBA). A new method for the diagnosis and detection of recurrence of bladder cancer].
Escaf Barmadah S; Martín Benito JL; Fernández Gómez JM; San Martín Blanco A; Pérez Gracia FJ; Rodríguez Martínez JJ
Arch Esp Urol; 1998 Mar; 51(2):129-36. PubMed ID: 9586309
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
el-Ahmady O; Halim AB; el-Din AG
Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer].
Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y
Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of tissue-polypeptide specific antigen (TPS) in bladder cancer.
Menendez V; Galan JA; Fernandez-Suarez A; Lopez S; Alcover J; Calpena R; Filella X
Anticancer Res; 2002; 22(6B):3713-6. PubMed ID: 12552981
[TBL] [Abstract][Full Text] [Related]
16. Serum tissue polypeptide antigen (TPA): monoclonal or polyclonal radio-immunometric assay for the follow-up of bladder cancer.
Bennink R; Van Poppel H; Billen J; Decoster M; Baert L; Mortelmans L; Blanckaert N
Anticancer Res; 1999; 19(4A):2609-13. PubMed ID: 10470203
[TBL] [Abstract][Full Text] [Related]
17. Urinary evaluation of tumor-associated antigens in urothelial bladder tumors.
Piana P; Casetta G; Cavallini A; Piantino P; Tizzani A
Prog Clin Biol Res; 1991; 370():179-84. PubMed ID: 1924448
[No Abstract] [Full Text] [Related]
18. [Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers].
Ruibal A; Durán P; Lafuerza A; Bodi R; Solé LA; Rubio D; Ibarz L; De Torres JA; Domenech-Torné FM; Salvador L
Rev Esp Oncol; 1984; 31(3):409-14. PubMed ID: 6546169
[TBL] [Abstract][Full Text] [Related]
19. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia.
Tramonti G; Ferdeghini M; Donadio C; Norpoth M; Annichiarico C; Bianchi R; Bianchi C
Cancer Detect Prev; 2000; 24(1):86-90. PubMed ID: 10757127
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
